Related Experiment Video

Updated: Dec 6, 2025

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
05:30

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies

Published on: January 31, 2025

891

Convalescent Plasma for Patients With Severe Coronavirus Disease 2019 (COVID-19): A Matched Cohort Study

Ralph Rogers1, Fadi Shehadeh1, Evangelia K Mylona1

  • 1Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|October 10, 2020
PubMed

Insights

Convalescent plasma (CP) did not significantly reduce mortality or improve hospital discharge rates in severe COVID-19 patients. However, elderly patients receiving CP showed a trend toward better outcomes, warranting further investigation in targeted studies.

Area of Science:

  • Infectious Diseases
  • Hematology
  • Critical Care Medicine

Background:

  • The effectiveness of convalescent plasma (CP) as a treatment for coronavirus disease 2019 (COVID-19) remains uncertain.
  • Severe COVID-19 cases present a significant challenge, necessitating evaluation of potential therapeutic interventions.

Purpose of the Study:

  • To evaluate the impact of convalescent plasma (CP) treatment on in-hospital mortality and hospital discharge rates in patients with severe COVID-19.
  • To identify potential subgroups that may benefit from CP therapy.

Main Methods:

  • A matched cohort analysis comparing hospitalized severe COVID-19 patients who received CP with a control group.
  • Univariate and multivariate Cox proportional-hazards models were used to assess mortality risk.
  • Stratified log-rank analysis examined the time to hospital discharge.

Main Results:

  • No significant difference in in-hospital mortality was observed between the CP group (12.5%) and the control group (15.8%).
  • The overall rate of hospital discharge did not differ significantly between groups (RR 1.28, 95% CI .91-1.81).
  • A significantly increased rate of hospital discharge was noted in patients aged 65 or older who received CP (RR 1.86, 95% CI 1.03-3.36).
  • A higher frequency of transfusion reactions was observed in the CP group (2.8% per unit transfused).

Conclusions:

  • Convalescent plasma treatment did not demonstrate a significant benefit in reducing mortality or improving discharge rates for severe COVID-19 patients.
  • A potential positive effect of CP was observed in elderly patients (≥65 years), suggesting this subgroup may benefit.
  • Further adequately powered randomized controlled trials are recommended to investigate CP efficacy specifically in the elderly COVID-19 population.
Abstract

Keywords:
COVID-19SARS-CoV-2convalescent plasmaefficacy

More Related Videos

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-1908:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

3.2K
Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals06:46

Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals

Published on: January 5, 2016

17.7K

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
840
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
131
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
143
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
118